Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Next Generation Drug Conjugates Market: Antibody-Drug Conjugate Oncology Demand, Radionuclide Conjugate Application Growth, and GalNAc-Oligonucleotide Platform Adoption to Drive Strong Market Expansion Through 2035

The global Next Generation Drug Conjugates (NDCs) Market was valued at USD 16,542.9 million in 2025 and is projected to expand at a strong CAGR of 12.4%, reaching approximately USD 47,370.5 million by 2035. This growth trajectory is being driven by sustained clinical and commercial demand for antibody-drug conjugates in oncology treatment, growing application of peptide-radionuclide and antibody-radionuclide conjugates, and continued advancement of GalNAc-oligonucleotide conjugate platforms for liver-directed diseases. The market comprises commercially available, regulatory-stage, and clinical-pipeline conjugate products applied across oncology, hereditary transthyretin amyloidosis, and a broadening set of therapeutic indications.

The market’s strong 12.4% CAGR reflects the maturation of targeted conjugate technology as a validated therapeutic class spanning oncology and non-oncology indications, generating structured demand from hospitals and specialty treatment centers above discretionary specialty pharmaceutical demand growth. Sustained commercial performance of established antibody-drug conjugates continues to support procurement volumes, while radionuclide conjugate applications represent a distinct and rapidly growing therapeutic category among precision oncology developers. Coverage extending across multiple conjugate architectures, targeting ligands, and payload types underscores the breadth of clinical and manufacturing infrastructure now supporting this category.

Executive Snapshot

How does antibody-drug conjugate oncology demand drive the next generation drug conjugates market?
Cancer treatment centers continue to administer established antibody-drug conjugates including Enhertu and Trodelvy for breast, lung, and other solid tumor indications, establishing this conjugate class as the largest single contributor to market revenue. As clinical evidence continues to support expanded indications and earlier treatment lines, procurement associated with ADCs is expected to remain the dominant category through the forecast period.

What role does radionuclide conjugate application growth play in market expansion?
Oncology treatment centers increasingly administer peptide-radionuclide and antibody-radionuclide conjugates such as Pluvicto for prostate cancer treatment, sustaining structured demand from specialized nuclear medicine and oncology center accounts. Continued clinical pipeline investment in alpha-emitter and beta-emitter radionuclide conjugates is generating demand that increasingly exceeds levels attributable to conventional small-molecule payload conjugates.

How does GalNAc-oligonucleotide platform adoption sustain market growth?
Biopharmaceutical developers continue to advance ligand-oligonucleotide conjugates, including GalNAc-conjugated siRNA products such as Amvuttra, for liver-directed genetic and metabolic diseases, sustaining structured demand above conventional antibody-conjugate application baselines. Continued clinical success in hereditary transthyretin amyloidosis and primary hyperlipidemia indications is generating sustained demand for this conjugate architecture.

What is driving demand for next-generation drug conjugates in hematological malignancy applications?
Developers pursuing conjugate candidates for hematological malignancies continue to extend targeted conjugate technology beyond its historical solid tumor core, generating incremental demand among clinical-stage biopharmaceutical developers pursuing broader addressable patient populations.

How does targeted radiation payload demand sustain the market?
Biopharmaceutical developers increasingly specify alpha-emitter and beta-emitter radionuclide payloads for their targeted cytotoxic properties in prostate cancer and neuroendocrine tumor applications, sustaining structured demand from developers pursuing differentiated conjugate mechanisms of action.

Which next-generation drug conjugate market segments are growing fastest?
The fastest-growing segments include antibody-radionuclide and peptide-radionuclide conjugates, GalNAc-oligonucleotide conjugates for liver-directed disease, regulatory review and near-launch pipeline products, and hematological malignancy indications as clinical evidence continues to expand.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Next Generation Drug Conjugates Market

  • Antibody–small molecule conjugates sustaining the leading share of market revenue: Established oncology ADC products continue to represent the largest single conjugate type by commercial procurement value across the category.
  • Breast cancer and prostate cancer indications sustaining the leading revenue share: Commercial performance of leading ADC and radioligand conjugate products in these indications continues to anchor overall market revenue.
  • Antibody–radionuclide and peptide–radionuclide conjugates sustaining accelerating growth above conventional payload types: Clinical and commercial success of targeted radiation conjugates continues to direct developer investment toward this differentiated mechanism.
  • GalNAc-based ligand–oligonucleotide conjugates sustaining structured liver-directed disease demand: Established clinical success in hereditary transthyretin amyloidosis and related indications continues to support this conjugate architecture.
  • Regulatory review and near-launch pipeline products sustaining anticipatory market positioning: As regulatory submissions progress, treatment centers and payers continue to prepare for an expanding set of newly approved conjugate therapeutics.
  • Hematological malignancy and non-oncology indications sustaining a broadening addressable market: Extension of conjugate technology beyond solid tumor oncology continues to expand the category’s overall addressable patient population.

Market Segmentation: Next Generation Drug Conjugates Market

By Product Type
  • Enhertu
  • Pluvicto
  • Amvuttra
  • Trodelvy
  • Sacituzumab Tirumotecan
  • Patritumab Deruxtecan
  • ²²⁵Ac-PSMA-617
  • Other Commercialized Products
  • Other Pipeline Products
By Conjugate Type
  • Antibody–Small Molecule Conjugates
  • Antibody–Oligonucleotide Conjugates
  • Peptide–Radionuclide Conjugates
  • Ligand–Oligonucleotide Conjugates
  • Antibody–Radionuclide Conjugates
  • Small Molecule–Drug Conjugates
  • Peptide–Drug Conjugates
  • Other Next-Generation Drug Conjugates
By Indication
  • Breast Cancer
  • Prostate Cancer
  • Hematological Malignancies
  • Lung Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Liver-Related Diseases
  • Hereditary Transthyretin Amyloidosis (hATTR)
  • Primary Hyperlipidemia
  • Other Cancers
  • Other Non-Oncology Indications
By Target
  • HER2
  • HER3
  • TROP2
  • PSMA
  • ASGPR
  • Somatostatin Receptor
  • Other Tumor / Tissue Targets
By Payload Type
  • Small-Molecule Payloads
  • Oligonucleotide Payloads
    • siRNA
    • Antisense Oligonucleotides
    • Other RNA-Based Payloads
  • Radionuclide Payloads
    • Alpha Emitters
    • Beta Emitters
    • Other Radioisotopes
  • Other Payloads
By Disease Stage
  • Early-Stage Disease
  • Locally Advanced Disease
  • Metastatic Disease
  • Relapsed / Refractory Disease
  • Advanced / Unresectable Disease
By Route of Administration
  • Intravenous
  • Subcutaneous
  • Intramuscular
  • Other Routes
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Distribution Channel
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Specialty Distributors
  • Direct Sales
  • Other Distribution Channels
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By Dosing Frequency
  • Once-Daily
  • Once-Weekly
  • Once-Monthly
  • Other Extended-Dosing Regimens
By End User
  • Hospitals
  • Comprehensive Cancer Centers
  • Specialty Clinics
  • Academic Medical Centers
  • Specialty Treatment Centers
  • Home Care Settings
  • Other Healthcare Settings
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Next Generation Drug Conjugates Market

  1. Sustained commercial performance of established ADCs driving continued oncology procurement: Expanding indications and earlier treatment line adoption continue to support structured ADC demand above the broader oncology therapeutics baseline.
  2. Growing clinical pipeline investment in radionuclide conjugate technology: Alpha-emitter and beta-emitter conjugate development continues to attract structured investment from precision oncology developers.
  3. Continued clinical success in liver-directed genetic disease supporting GalNAc conjugate adoption: Established performance in hereditary transthyretin amyloidosis and related indications continues to support sustained conjugate platform investment.
  4. Extension into hematological malignancies broadening the addressable therapeutic market: Developers pursuing conjugate candidates beyond solid tumor oncology continue to generate incremental demand from clinical-stage biopharmaceutical accounts.
  5. Maturing regulatory pipelines supporting an approaching wave of commercial launches: A growing pipeline of late-stage candidates continues to focus treatment center and payer attention on the category’s next phase of expansion.
  6. Sustained developer interest in differentiated mechanisms of action supporting conjugate diversification: Continued investment across small-molecule, oligonucleotide, and radionuclide payload types continues to broaden the category’s therapeutic scope.

Regional Outlook: Next Generation Drug Conjugates Market

  • North America: The United States accounts for the largest share of regional demand, supported by broad payer coverage, extensive cancer center and specialty treatment infrastructure, and leading commercial performance of established conjugate products; regional manufacturers continue to expand production capacity to accommodate this demand.
  • Europe: Germany, the United Kingdom, and France anchor regional demand, supported by growing specialized treatment center capacity and consistent clinical adoption across oncology and liver-directed disease indications; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as treatment access expands and regional biopharmaceutical developers advance their own conjugate pipelines; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cancer and treatment centers begin offering next-generation conjugate therapies; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Next Generation Drug Conjugates Market

Key Players
AstraZeneca plc, Daiichi Sankyo Company, Limited, Novartis AG, Alnylam Pharmaceuticals, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Roche Holding AG, Pfizer Inc., Seagen Inc. (Pfizer Inc.), ImmunoGen, Inc. (AbbVie Inc.), Ionis Pharmaceuticals, Inc., Sirnaomics, Inc., Bristol Myers Squibb Company, Sanofi S.A., Zealand Pharma A/S

  • Daiichi Sankyo Company, Limited [March 2026] — confirmed continued expansion of its antibody-drug conjugate portfolio and manufacturing capacity, with the company noting sustained global demand across breast, lung, and gastric cancer indications.
  • Novartis AG [December 2025] — reported continued expansion of its radioligand conjugate manufacturing capacity supporting Pluvicto, with the company noting sustained patient demand across prostate cancer treatment settings.
  • Alnylam Pharmaceuticals, Inc. [September 2025] — confirmed continued commercial growth of its GalNAc-conjugated siRNA portfolio supporting Amvuttra, with the company reporting structured demand growth across hereditary transthyretin amyloidosis treatment accounts.

Consultant POV

The Next Generation Drug Conjugates Market’s strong 12.4% CAGR from USD 16,542.9 million in 2025 toward approximately USD 47,370.5 million by 2035 is anchored in sustained antibody-drug conjugate oncology demand, growing radionuclide conjugate application activity, and continued GalNAc-oligonucleotide platform adoption. Sustained clinical and manufacturing investment from companies including Daiichi Sankyo Company, Limited, Novartis AG, and Alnylam Pharmaceuticals, Inc. confirms the Next Generation Drug Conjugates Market will sustain strong growth through 2035.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report